SCHEMBL31551850

SCHEMBL31551850

CC1(C)OC(=O)C(C(=O)Cc2ccc(F)c(F)c2)C(=O)O1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 1/20 0.41
HIF1A Q16665 1/20 0.40
ALDH1A1 P00352 3/20 0.38
MAPT P10636 2/20 0.38
KDM4E B2RXH2 1/20 0.38
HTT P42858 1/20 0.38
SIGMAR1 Q99720 2/20 0.37
GLA P06280 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
HCAR3 P49019 1/20 0.36
HCAR2 Q8TDS4 1/20 0.36
MAOA P21397 2/20 0.35
MAOB P27338 2/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
RIPK1 Q13546 1/20 0.35
MAPK8 P45983 1/20 0.34
DPP4 P27487 1/20 0.34
DPP8 Q6V1X1 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24535005 0.88 PIK3CA (0.43) BACE1ALDH1A1MAPTKDM4EHTT
SCHEMBL29679895 0.88 KDM4E (0.39) BACE1HIF1AALDH1A1MAPTKDM4E
SCHEMBL29080116 0.88 KDM4E (0.39) BACE1HIF1AALDH1A1MAPTKDM4E
SCHEMBL29679997 0.88 PIK3CA (0.43) BACE1ALDH1A1MAPTKDM4EHTT
SCHEMBL25353819 0.81 L3MBTL1 (0.40) BACE1ALDH1A1GLANPSR1
SCHEMBL411648 0.80 BACE1 (0.40) BACE1GLANPSR1HCAR3HCAR2
SCHEMBL21176880 0.80 HPGD (0.46) BACE1ALDH1A1MAPTKDM4EHTT
SCHEMBL28978262 0.79 BACE1 (0.42) BACE1GLANPSR1
SCHEMBL31048329 0.78 BACE1 (0.40) BACE1ALDH1A1MAPTKDM4EHTT
SCHEMBL30706753 0.78 BACE1 (0.40) BACE1ALDH1A1MAPTKDM4EHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12528828-B2 Substituted pyrido[4,3-d]pyrimidines as KRAS modulators ALTEROME THERAPEUTICS, INC. (US) 2026-01-20 US disclosed
US-20250346610-A1 SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORS ALTEROME THERAPEUTICS INC (US) 2025-11-13 US disclosed
US-12466842-B2 Substituted pyrido [4,3-d]pyrimidines as KRAS modulators ALTEROME THERAPEUTICS, INC. (US) 2025-11-11 US disclosed
US-20250282799-A1 SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORS ALTEROME THERAPEUTICS, INC. 2025-09-11 US disclosed
US-20250179093-A1 KRAS MODULATORS ALTEROME THERAPEUTICS, INC. 2025-06-05 US disclosed
WO-2025064542-A1 KRAS MODULATORS ALTEROME THERAPEUTICS, INC. (US) 2025-03-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250179093-A1 KRAS MODULATORS KRAS, NRAS, HRAS BACE1 2965/4885HIF1A 1414/4885ALDH1A1 4071/4885
US-20250346610-A1 SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORS KRAS, NRAS, HRAS BACE1 3110/4885HIF1A 2289/4885ALDH1A1 3593/4885
US-12466842-B2 Substituted pyrido [4,3-d]pyrimidines as KRAS modulators KRAS, NRAS, HRAS BACE1 3110/4885HIF1A 2289/4885ALDH1A1 3593/4885
US-20250282799-A1 SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORS KRAS, NRAS, HRAS BACE1 3110/4885HIF1A 2289/4885ALDH1A1 3593/4885
US-12528828-B2 Substituted pyrido[4,3-d]pyrimidines as KRAS modulators KRAS, NRAS, HRAS BACE1 2074/4885HIF1A 2716/4885ALDH1A1 1854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.